UNRESECTABLE HEPATOCELLULAR CARCINOMA

This study tested whether adding the chemotherapy drug doxorubicin to the targeted therapy sorafenib helps people with advanced liver cancer live longer. Over 350 patients received either sorafenib alone or sorafenib plus doxorubicin. The main goal was to compare overall survival…

This small, completed phase II study tested the safety of combining two drugs—atezolizumab (an immunotherapy) and bevacizumab (a blood vessel blocker)—in 6 people with advanced liver cancer who also had moderate cirrhosis (Child-Pugh B7 or B8). The goal was to see if this treatme…

This study looked at the safety of two drugs, IMJUDO and IMFINZI, given together or alone to 1,200 people with advanced liver cancer that cannot be removed by surgery. The main goal was to track any side effects that happen in everyday medical use. The study is now complete and h…

This study looked at 200 people with advanced liver cancer whose first treatment (bevacizumab plus sintilimab) stopped working. Researchers compared two second-line options: a PD-1 inhibitor combined with either lenvatinib or regorafenib. The goal was to see which combo works bet…

This completed Phase 1 trial tested a new injection called NRT6003, which contains tiny radioactive beads (yttrium-90), in 40 people with liver cancer that could not be removed by surgery. The goal was to see if the treatment is safe and whether it can shrink tumors in the liver.…

This phase 2 trial tested whether a special PET scan using a radioactive tracer called 68Ga-PSMA can better detect advanced liver cancer that has spread. The tracer attaches to a protein found on liver cancer cells, making them visible on the scan. The study involved 29 adults wi…